News Release

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi's Treatment for Functional Symptoms of BPH Launched in the United States, Completing a Presence in Three Major Markets: Asia, Europe, and the United States

October 9, 1997

Tamsulosin, a treatment for the functional symptoms of benign prostatic hyperplasia (BPH) developed by Yamanouchi Pharmaceutical Co., Ltd., (Masayoshi Onoda, president), is being launched in the United States.

Through an agreement with U.S. licensee Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), headquartered in Ridgefield, Connecticut, the product is being sold under the brand name Flomax.

The clinical development of tamsulosin in the United States has been carried out by Yamanouchi U.S.A. Inc., headquartered in White Plains, New York. On behalf of Yamanouchi U.S.A., BIPI handled FDA filing procedures and obtained marketing approval in April 1997. Thus, BIPI played a crucial role in preparing for the introduction of tamsulosin into the U.S. market. Promotion to health professionals, including both office- and hospital-based urologists, began in September. On October 8, 1997, full-scale promotional activities in U.S. markets, including the primary care markets, started.

In the short term, BIPI will be supplied with bulk tamsulosin produced in Japan and packaged in Norman, Oklahoma, at a plant owned by Shaklee Corporati on, a Yamanouchi subsidiary headquartered in San Francisco, California. Construction of pharmaceutical production facilities on the site of Shaklee Corp oration's
plant in Norman, Oklahoma, is scheduled for completion in summer 1998, and shipments from that facility are expected to start in 1999.

Tamsulosin is an ethical drug developed by Yamanouchi to treat the functional symptoms of BPH, a condition that is afflicting a growing number of men as populations age. The product was introduced into the Japanese market under the brand name Harnal in 1993, and has secured the top share of the market for BPH treatments. Yamanouchi has designated tamsulosin one of the strategic products in its global development plans and has worked to foster the success of tamsulosin on a tripolar basis in Europe, North America, and Asia. The product's introduction in the United States, a country whose market for BPH-related treatments Yamanouchi estimates to be worth ¥50 billion annually, has been eagerly awaited.

In Europe, Yamanouchi Europe B.V. (YEU), based in Leiderdorp, the Netherlands, and boasting a strong regional marketing network, launched tamsulosin in the Netherlands in 1995 under the brand name Omnic. Since then, YEU has begun marketing the product, under various brand names, in 13 European countries. In such major markets as Germany, France, and Italy, YEU is marketing tamsulosin jointly with the Boehringer Ingelheim Group to promote the product's acceptance in the medical community. In the Netherlands, tamsulosin has already earned the leading market share among products of its kind, and further market growth is anticipated. YEU's plant in Meppel, the Netherlands, is being shifted to the production of tamsulosin. In addition, Dublin-based Yamanouchi Ireland Co., Ltd. (YICL), which is manufacturing bulk pharmaceuticals for European and U.S. markets, is moving forward with plans that will allow it to begin shipments of bulk tamsulosin in 1999. Upon completion, production at YICL and in Norman will
enable 100% of the tamsulosin sold in Europe and North America to be manufactured in those markets.

In Asia, the direct marketing of tamsulosin through subsidiaries began in 1996 in China and in 1997 in Korea and the Philippines. Future efforts will be directed toward continued market expansion, particularly in the countries of Southeast Asia.

With the U.S. market launch of tamsulosin, Yamanouchi has virtually achieved its goal of introducing this strategically important drug into the world's three principal drug markets
- the United States, Europe, and Japan.

Tamsulosin is expected to continue to make a significant contribution to the Company's overall performance.

<For reference>
Boehringer Ingelheim Pharmaceuticals, Inc.
Head Office: Ridgefield, Connecticut
Employees: Approximately 1,900
Principal Operations: Development, manufacture, and sales of pharmaceuticals and OTC dietary supplements
Shaklee Corporation
Head Office: San Francisco, California
Employees: Approximately 1,900
Principal Operations: Nutritional supplements, household goods, personal care products, food, horticultural products, licensed production of OTC drugs
Yamanouchi Europe B.V.
Headquarters: Leiderdorp, The Netherlands
Employees: About 1,200
Principal Operations: Research and Development, manufacture, and sales of pharmaceuticals
About benign prostatic hyperplasia (BPH)
The prostate gland is found only in men and surrounds the urethra just below the bladder. It may become enlarged with age or changes in the body's hormonal environment, causing the appearance of functional symptoms of benign prostatic hyperplasia, or BPH. BPH causes pressure on the urethra and an increase in the number of alpha1-receptors in the prostate, leading to excessive contraction of the smooth muscle of the urethra and thus resulting in dysuria, nocturia, and other symptoms.

Tamsulosin selectively blocks the alpha1-receptors in the prostate and the urethra, easing constriction of the urethra and alleviating these symptoms with almost no effect on the smooth muscle of the blood vessels, which would affect blood pressure.
Status of Tamsulosin
Marketed in: The Netherlands (September 1995), Finland (November 1995), Denmark (March 1996), the United Kingdom (May 1996), Germany (August 1996), France (September 1996), Ireland(November 1996), Greece (February 1997), Italy (March 1997), Czech Republic (April 1997), Russia (May 1997), Spain (June 1997), the United States (September 1997), Argentina (September 1996), China (July 1997), Korea (February 1997), the Philippines (July 1997)